Phase 2 N=9 Randomized Double-blind Treatment

Glenohumeral Cortisone Injection

Humeral Fractures

Bottom Line

View on ClinicalTrials.gov: NCT04216017 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Sep 2023

Primary outcome: Primary: American Shoulder Elbow Society Score — 46; 87 score on a scale

Study Design & Population

Study type: Interventional
Phase: Phase 2
Interventions: kenalog (Drug); Lidocaine (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: University of Washington
Primary completion: Apr 2022

Outcome Measures

Outcome	Result	p-value
PRIMARY American Shoulder Elbow Society Score	46; 87	—
SECONDARY Visual Analogue Scale	4; 1	—

Summary

The objective of this project is to determine if giving a cortisone injection to patients with proximal humerus fractures who have stiff shoulders recover their range of motion.

Eligibility Criteria

Inclusion Criteria

1.18-90

Proximal Humerus Fracture
Decreased range of motion at 6 wk follow-up
Likely to be available for follow up for 26 wks

Exclusion Criteria

Known drug allergy to kenalog or lidocaine
Unable to complete functional outcome
Pregnant Women

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04216017). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.